FDA’s Double Standard Re: Advisory Committee Membership Mon, 15 Nov 2004 FDA’s inexplicable actions–the latest being the removal of Dr. Curt Furberg from an FDA advisory committee for alleged "intellectual conflict of interest" – demonstrate hypocracy and intellectual dishonesty. Dr. Furberg independently analyzed the scientific data, concluding: "The result is…
AHRP Speaks Out AHRP Press Briefing 9/14/04: Antidepressants & suicide-related risks for children Open Letter to NIMH re Prozac & Concealed Suicide Attempts Open Letter to Officials at NIMH AHRP Briefing 2/2/04: Scientists present suicide evidence Conflicts of Interest policy – New York Times Phase I Drug Trials Used Foster…
THE ALLIANCE FOR HUMAN RESEARCH PROTECTION (AHRP) 142 West End Ave. Suite 28P, New York, NY 10023 Tel. No: 212-595-8974, Fax No: 212-595-9086 ***PRESS BRIEFING 2/2/04*** Statement by Vera Hassner Sharav, President, AHRP The Alliance for Human Research Protection is convening this press conference because we believe a fair and…
Ex-NIH Director Lifted conflict of interest rules, Now favors limits on Drug-Company Ties – LAT Sun, 14 Mar 2004 Former Director of the National Institutes of Health, Harold Varmus, MD, appeared before a blue ribbon panel convened by his former agency, ostensibly to shed light on conflict of interest at…
Reply to the American College of Neuropharmacology’s Report on SSRI and Suicidal Behavior in Children Jonathan Leo, Ph.D. Introduction The American College of Neuropsychopharmacology (ACNP) recently released an Executive Summary from its Task Force on SSRIs and Suicidal Behavior. The task force concluded that "taking Selective Serotonin Reuptake Inhibitors (SSRIs)…
ACNP Summary Report Criticized as “Junk Science” Sun, 25 Jan 2004 related links: Reply to ACNP Report – Jonathan Leo, Ph.D. FDA Sham Conflicts of Interest Policy Most of the National press coverage of the controversy swirling around the claims and counter claims about drug suicidal obsessive thinking and behavior…
Letter from David Healy, MD to Peter J. Pitts Executive Summary of suicidal evidence not addressed by FDA In the light of Traci Johnson’s death on February 7th 2004, will FDA obtain Pfizer’s entire folder on the 1982 Hindmarch study in which healthy volunteers were given Zoloft, and make a…
Success in academic psychiatry is not measured in the improvement of patients' mental health, but rather in quantifiable commercial tender.How many grants one brings to the university, how many publications one churns out each year, and how many corporate and professional advisory boards one serves on–and how much money one…
Psychiatry’s most powerful and influential key opinion leaders who belong to the American College of Neuropsychopharmacology (ACNP) have been caught off guard. The ACNP leadership is scrambling to overcome the scorn it has received following public disclosure about multiple breaches of ethics and professional standards of conduct. The College and…
A follow-up to news reports about the conflict of interest scandal that has engulfed not only Dr. Charles Nemeroff, former president and editor in chief of the official journal of the American College of Neuropsychopharmacology, but the College itself.
A notice from The American College of Neuropsychopharmacology, the inner sanctum of biological–predominantly drug-centered psychiatry–informs the
membership of the resignation of Dr. Charles Nemeroff, the Editor-in-Chief of its journal, Neuropsychopharmacology.
The harm done by journals’ failure to protect the integrity of science can hardly be overstated.
